Breaking News

Concert Achieves Avanir Milestone

August 28, 2014

Initiates Phase II trial of AVP-786 in major depressive disorder

Concert Pharmaceuticals has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals for the clinical progression of AVP-786. Avanir initiated dosing in a Phase II trial for the adjunctive treatment of major depressive disorder.
 
Avanir has worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan (d-DM) compounds, which also have potential to treat neurological and psychiatric disorders.
 
Concert is eligible to receive additional milestones based on certain clinical, regulatory and commercial targets. Avanir will continue to have overall responsibility for R&D and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive royalties on sales.
 
“We are very pleased by Avanir’s progress with AVP-786’s clinical development, resulting in a second development milestone to Concert from this program,” said Roger Tung, Ph.D., president and chief executive officer of Concert Pharmaceuticals.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers